Esperion Therapeutics (ESPR) Receivables (2020 - 2026)

Esperion Therapeutics' Receivables history runs 7 years deep, the most recent figure standing at $132.4 million for Q1 2026.

• Quarterly Receivables rose 62.81% year-over-year to $132.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132.4 million (up 62.81% YoY) and the FY2025 annual result came in at $140.2 million, up 74.93% from the prior year.
• Receivables was $132.4 million for Q1 2026 at Esperion Therapeutics, down from $140.2 million in the prior quarter.
• Across five years, Receivables topped out at $140.2 million in Q4 2025 and bottomed at $25.1 million in Q1 2022.
• A 5-year average of $66.5 million and a median of $54.6 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables climbed 12.86% — and 2025, when it soared 78.51%.
• Esperion Therapeutics' Receivables stood at $33.7 million in 2022, then jumped by 43.78% to $48.5 million in 2023, then soared by 65.26% to $80.1 million in 2024, then jumped by 74.93% to $140.2 million in 2025, then slipped by 5.59% to $132.4 million in 2026.
• Business Quant data shows ESPR's Receivables at $132.4 million in Q1 2026, $140.2 million in Q4 2025, and $119.0 million in Q3 2025.